Opti­Nose files for $100M IPO; GSK wins three-in-one COPD OK

⇨ Yard­ley, PA-based Opti­Nose is join­ing the grow­ing line for Nas­daq, fil­ing for a $100 mil­lion IPO, ac­cord­ing to the S-1. The fil­ing came right on the heels of an OK for XHANCE — pre­vi­ous­ly re­ferred to by the de­vel­op­ment name OPN-375 — for the treat­ment of nasal polyps.

GSK got some good news to­day, win­ning FDA ap­proval of the first three-in-one once-dai­ly ther­a­py for COPD. The move comes af­ter the EMA en­dorsed the in­haler last week.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.